Novo Nordisk A/S (NVO)
| Market Cap | 270.86B |
| Revenue (ttm) | 21.66B |
| Net Income (ttm) | 6.84B |
| Shares Out | 2.31B |
| EPS (ttm) | 3.24 |
| PE Ratio | 37.45 |
| Forward PE | 27.86 |
| Dividend | $1.60 (1.32%) |
| Ex-Dividend Date | Aug 12, 2022 |
| Volume | 2,436,787 |
| Open | 121.19 |
| Previous Close | 121.23 |
| Day's Range | 121.14 - 122.51 |
| 52-Week Range | 91.51 - 122.51 |
| Beta | 0.32 |
| Analysts | Buy |
| Price Target | 116.63 (-3.9%) |
| Earnings Date | Nov 2, 2022 |
About NVO
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration a... [Read more]
Financial Performance
In 2021, Novo Nordisk's revenue was 140.80 billion, an increase of 10.91% compared to the previous year's 126.95 billion. Earnings were 47.76 billion, an increase of 13.33%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 35 analysts, the average rating for NVO stock is "Buy." The 12-month stock price forecast is 116.63, which is a decrease of -3.89% from the latest price.
News
3 Healthcare Stocks That Could Set You Up For Life
All offer products that are invaluable to their respective audiences.
Novo Nordisk invests DKK 5.4 bn Danish kroner in expansion of clinical manufacturing facilities in Bagsværd, Denmark
Bagsværd , Denmark, 22 November 2022 – Novo Nordisk today announced plans to invest 5.4 bn Danish kroner in the expansion of existing facilities in Bagsværd. The plans also include the construction of a...
Novo Nordisk A/S – Share repurchase programme
Bagsværd , Denmark, 21 November 202 2 – On 4 November 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Coun...
BAYRY vs. NVO: Which Stock Is the Better Value Option?
BAYRY vs. NVO: Which Stock Is the Better Value Option?
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 15 November 202 2 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated pers...
Novo Nordisk's Smart Connected Pens Are Now Compatible with Abbott's FreeStyle LibreLink App
GATWICK, England--(BUSINESS WIRE)--This material is intended for UK medical and pharmaceutical trade media only.
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd , Denmark, 4 November 2022 – This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accord...
Novo Nordisk A/S purchases B shares worth DKK 3,582 million from Novo Holdings A/S under the 2022 share repurchase pr...
Bagsværd , Denmark, 04 November 2022 – Today, Novo Nordisk A/S has entered into an agreement to purchase 4,207,500 B shares of DKK 0.20 at a value of DKK 3,582 million from Novo Holdings A/S. The transa...
3 Unstoppable Investments Everyone Needs in Their Portfolio
Not every company can thrive in -- or even survive -- a wobbly economy.
Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates
Novo Nordisk (NVO) reports better-than-expected Q3 results. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
Novo Nordisk Is Throwing Down The Gauntlet In Weight Loss As Eli Lilly Ramps Up
Novo Nordisk is planning to boost production for weight-loss shot Wegovy as Eli Lilly angles for approval. NVO stock surged Wednesday.
Novo Nordisk to increase manufacturing capacity of weight-loss drugs
Novo Nordisk said it will boost manufacturing capacity for future obesity drug launches and worry less about marketing and advertising after a bungled market introduction of its Wegovy injection last year.
Novo Nordisk sees faster profit growth on demand for diabetes drug Ozempic
Danish drugmaker Novo Nordisk raised its full-year earnings outlook on strong sales of diabetes treatment Ozempic, also reporting a better-than-expected profit.
Novo Nordisk lifts guidance as earnings beat expectations
Danish pharmaceutical company Novo Nordisk AS NOVO.B, -2.21% NVO, -2.21% on Wednesday raised full-year guidance and reported a third-quarter net profit that beat expectations amid strong demand for its ...
Novo Nordisk's sales increased by 26% in Danish kroner and by 16% at constant exchange rates to DKK 128.9 billion in ...
Financial report for the period 1 January 2022 to 30 September 2022
BAYRY or NVO: Which Is the Better Value Stock Right Now?
BAYRY vs. NVO: Which Stock Is the Better Value Option?
BIOCORP and NOVO NORDISK Strengthen Their Partnership With a New Agreement on Mallya® Smart Sensor
ISSOIRE, France--(BUSINESS WIRE)-- #digitalhealth--Regulatory News: BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR), a French company specialized in the design, development, and manufact...
Prediction: This Could Be This Company's Next Billion-Dollar Product
It would be a major addition to an already rich portfolio.
Novo Nordisk announces the completion of the Forma Therapeutics acquisition
Bagsværd, Denmark, 14 October 2022 – Novo Nordisk today announced that the acquisition of Forma Therapeutics Holdings, Inc. (Forma), announced on 1 September 2022, has been completed.
Novo Nordisk is ‘a company investors should take a look at,' analyst says
Cowen Vice President Equity Research Michael Nedelcovych joins Yahoo Finance Live to discuss Elon Musk touting a prescription weight-loss drug, the company Novo Nordisk, and U.S. adults living with obes...
Will Acquisitions Help Novo Nordisk (NVO) Combat Stiff Rivalry?
Novo Nordisk (NVO) expects new acquisitions to diversify its portfolio of marketed drugs and help combat the stiff competition in the diabetes market.
Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program
WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop...
FORMA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Ad...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Forma Therapeutics...
Carmot Therapeutics Announces Significant Leadership Team Expansion with Anne Phillips, MD, FRCPC Previously SVP Novo...
BERKELEY, Calif.--(BUSINESS WIRE)--Carmot Therapeutics, Inc. (Berkeley, CA), a clinical-stage biotechnology company applying its proprietary drug discovery platform, Chemotype Evolution, to discover and...